Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Natalizumab

Catalog #:   DHC98801 Specific References (99) DATASHEET
Host species: Humanized
Isotype: IgG4-kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHC98801

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG4-kappa

Clonality

Monoclonal

Target

ITGA4, CD49d, CD49 antigen-like family member D, CD49D, VLA-4 subunit alpha, Integrin alpha-IV, Integrin alpha-4

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P13612

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

AN 100226, BG00002, CAS: 189261-10-7

Clone ID

Natalizumab

Data Image
  • SDS-PAGE
    SDS PAGE for Natalizumab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Natalizumab in Multiple Sclerosis: Long-Term Management, PMID: 28468254

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies, PMID: 31589278

Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring, PMID: 33072089

Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial, PMID: 32591475

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing, PMID: 31515290

A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis, PMID: 30639651

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP), PMID: 32234967

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension, PMID: 29545067

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients, PMID: 32056253

Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial, PMID: 32690785

The risk of PML from natalizumab, PMID: 30784548

Natalizumab-Associated Primary Central Nervous System Lymphoma, PMID: 28962961

Natalizumab in relapsing-remitting multiple sclerosis, PMID: 27008031

A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis, PMID: 26835603

Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker, PMID: 32156774

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study, PMID: 28209331

The role of natalizumab in the treatment of multiple sclerosis, PMID: 20615052

Use of natalizumab in multiple sclerosis: current perspectives, PMID: 27413840

Natalizumab treatment of multiple sclerosis: new insights, PMID: 28004598

Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology, PMID: 28167648

Natalizumab-associated progressive multifocal leukoencephalopathy in Germany, PMID: 30952796

Natalizumab: a new therapy for acute ischemic stroke?, PMID: 27476862

[Natalizumab treatment in multiple sclerosis], PMID: 26156254

Natalizumab induced cutaneous sarcoidosis-like reaction, PMID: 31108403

Natalizumab in secondary progressive multiple sclerosis, PMID: 29545068

Treatment of natalizumab-associated PML with filgrastim, PMID: 31139690

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS, PMID: 31355324

We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?, PMID: 24417188

Dosing interval of natalizumab in MS: Do good things come to those who wait?, PMID: 31515289

Natalizumab for induction of remission in Crohn's disease, PMID: 30068022

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?, PMID: 31452081

Gynecological adverse effects of natalizumab administration: Case report and review of the literature, PMID: 30032043

Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy, PMID: 27456891

Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification, PMID: 28228564

[Natalizumab], PMID: 26480703

Spanish consensus on the use of natalizumab (Tysabri®)-2013, PMID: 24360652

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study, PMID: 33082194

Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results, PMID: 33205373

Exposure to natalizumab during pregnancy and lactation is safe - Commentary, PMID: 32508210

Exposure to natalizumab during pregnancy and lactation is safe - No, PMID: 32508200

Exposure to natalizumab during pregnancy and lactation is safe - Yes, PMID: 32508253

Pharmacodynamics of natalizumab extended interval dosing in MS, PMID: 32019876

Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis, PMID: 29353737

Clinical evaluation of natalizumab for formulary consideration, PMID: 20626228

Prediction of natalizumab anti-drug antibodies persistency, PMID: 29336205

Therapeutic drug monitoring of natalizumab, PMID: 30485149

Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis, PMID: 28641055

Erythroblast appearance associated with natalizumab, PMID: 30711880

Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis, PMID: 31452082

Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies, PMID: 27475049

Treatment Options for the Comorbidity of Multiple Sclerosis With Other Chronic Inflammatory Diseases., PMID:40526577

A comparison of JC virus assay performance provided with originator and biosimilar natalizumab., PMID:40515643

Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?, PMID:40515642

Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing., PMID:40515640

'Should natalizumab be used despite JC virus positivity? Yes'., PMID:40515591

Effectiveness of anti-CD20 therapies following natalizumab discontinuation: insights from a cohort study., PMID:40505538

What Is the Evidence on Immunomodulators and Immunosuppressants for Progressive Multiple Sclerosis? - A Cochrane Review Summary with Commentary., PMID:40485316

De-escalation of disease modifying therapies: A retrospective, observational single center study., PMID:40480031

The Italian Multiple Sclerosis Register Experience With Cladribine: Impact on Relapses, PIRA, and Treatment Sequencing Strategies Evaluation., PMID:40472290

A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS)., PMID:40465056

Approach to JCV testing with natalizumab biosimilar: a UK consensus statement., PMID:40460616

Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry., PMID:40455371

Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study., PMID:40451284

Real-world evidence from Türkiye on cancer risk and treatment exposure in multiple sclerosis: A histopathology-verified, registry-based study., PMID:40449191

Should natalizumab be used despite JC virus positivity? No., PMID:40443199

Optimizing treatment for pediatric multiple sclerosis., PMID:40443188

Should natalizumab be used despite JC virus positivity?-Commentary., PMID:40443181

Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with Natalizumab., PMID:40442571

Correction: Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study., PMID:40423827

Risk of stroke under disease modifying therapies for multiple sclerosis: a systematic review., PMID:40416416

Natalizumab-induced autoimmune liver injury., PMID:40414422

Natalizumab-induced autoimmune liver injury., PMID:40398815

Changes in circulating pro-inflammatory lymphocytes and cortical excitability with extended-interval natalizumab dosing in multiple sclerosis., PMID:40397308

Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study., PMID:40397068

Interventions promoting remyelination in multiple sclerosis: a systematic review of clinical trials., PMID:40393003

Comparative Efficacy and Safety of Extended Versus Standard Interval Dosing of Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients: A Multicenter Analysis., PMID:40387571

Pediatric Multiple Sclerosis: A Systematic Exploration of Effectiveness in Current and Emerging Therapeutics., PMID:40381455

Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab., PMID:40345115

Long-term safety evaluation of natalizumab during pregnancy and lactation in patients with multiple sclerosis., PMID:40332701

Cost-effectiveness of ofatumumab for the treatment of relapsing forms of multiple sclerosis in the United Arab Emirates., PMID:40303316

Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study., PMID:40296363

Recrudescence of Natalizumab-Induced Pneumonitis and Peripheral Hypereosinophilia: Case Report and Literature Review., PMID:40292235

Selective IgM Hypogammaglobulinemia and Multiple Sclerosis Treated with Natalizumab and Ofatumumab: A Case Report., PMID:40278334

Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells., PMID:40277931

Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosis., PMID:40254626

Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy., PMID:40236791

Generics, Biosimilars and Follow-On Non-Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists., PMID:40231751

Serological screening and Vaccine Update in a cohort of Multiple Sclerosis Patients as a strategy to prevent infection reactivation during immunosuppressant therapy., PMID:40220724

Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy., PMID:40220155

Impact of Natalizumab on Productivity and Ability to Work in Patients with Multiple Sclerosis in France: The TITAN Study., PMID:40208417

Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk., PMID:40197186

Acta neurologica belgica regarding the manuscript entitled 'Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis'., PMID:40186744

Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems., PMID:40186719

Pyoderma gangrenosum in a patient with multiple sclerosis under natalizumab treatment: a case report., PMID:40175973

Trends in the real-world management of patients with active relapsing-remitting multiple sclerosis treated with natalizumab (TYSABRI®) in France: An analysis of the PMSI database over five years (2019-2023)., PMID:40169334

Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis., PMID:40163140

Infection toxicity assessment of tumor necrosis factor α inhibitors in the treatment of IBD: a real-world study based on the US food and drug administration adverse events reporting system (FAERS)., PMID:40156444

No evidence of fluctuations in daily step count between infusions in people with multiple sclerosis treated with anti-CD20 monoclonal antibodies., PMID:40144903

Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura., PMID:40134425

Datasheet

Document Download

Research Grade Natalizumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Natalizumab [DHC98801]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only